Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918642 | 0.86 | MMP1 (0.50) | NPC1RAB9ACYP3A4SMN1; SMN2HPGD | |
| SCHEMBL3971405 | 0.77 | NPC1 (0.56) | NPC1RAB9AMAOB | |
| SCHEMBL3064569 | 0.77 | MAOB (0.58) | MAOB | |
| SCHEMBL3967573 | 0.77 | PARP15 (0.60) | NPC1RAB9ASMN1; SMN2ALDH1A1MMP2 | |
| SCHEMBL3969644 | 0.77 | MAOB (0.57) | MAOB | |
| SCHEMBL1067948 | 0.77 | MAOB (0.65) | MAOB | |
| SCHEMBL5972565 | 0.77 | NPC1 (0.45) | NPC1RAB9ACYP3A4SMN1; SMN2HPGD | |
| SCHEMBL10878729 | 0.74 | RAB9A (0.65) | NPC1RAB9ACYP3A4SMN1; SMN2HPGD | |
| SCHEMBL25568056 | 0.74 | NPC1 (0.83) | NPC1RAB9ACYP3A4SMN1; SMN2HPGD | |
| SCHEMBL920177 | 0.74 | SCN3A (0.65) | ALDH1A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-11-14 | — | — | US | claimed |
| EP-1032377-A4 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2006-06-14 | — | — | EP | claimed |
| US-20030130295-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2003-07-10 | — | — | US | claimed |
| US-6479484-B1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE DISCOVERY THAT THESE COMPOUNDS ACT AS BLOCKERS OF SODIUM CHANNELS; PAIN RELIEVERS, TREATMENT OF ARRYTHMIA, LOCAL ANESTHETICS | EURO-CELTIQUE S.A. (LU) | 2002-11-12 | — | — | US | claimed |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2002-02-07 | — | — | US | claimed |
| EP-1032377-A1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2000-09-06 | — | — | EP | claimed |
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-11-14 | — | — | US | disclosed |
| US-8426431-B2 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2201945-B1 | Use of substituted 2-aminoacetamides for treating or ameliorating anxiety | PURDUE NEUROSCIENCE COMPANY (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-2201944-B1 | Use of substituted 2-aminoacetamides for treating, preventing or ameliorating manic depression | PURDUE NEUROSCIENCE COMPANY (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20110269785-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2011-11-03 | — | — | US | disclosed |
| US-7872127-B2 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1032377-B1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | PURDUE NEUROSCIENCE COMPANY (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20030130295-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2003-07-10 | — | — | US | disclosed |
| US-6500825-B2 | SODIUM CHANNEL BLOCKERS USED TO TREAT AMYOTROPHIC LATERAL SCLEROSIS; ANALGESICS, ANTICONVULSANTS, ANTIDEPRESSANTS, LOCAL ANESTHETICS AND ANTIARRHYTHMICS | EURO-CELTIQUE S.A. (LU) | 2002-12-31 | — | — | US | disclosed |
| US-6479484-B1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE DISCOVERY THAT THESE COMPOUNDS ACT AS BLOCKERS OF SODIUM CHANNELS; PAIN RELIEVERS, TREATMENT OF ARRYTHMIA, LOCAL ANESTHETICS | EURO-CELTIQUE S.A. (LU) | 2002-11-12 | — | — | US | disclosed |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | PURDUE PHARMA LTD. | 2002-03-28 | — | — | US | disclosed |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2002-02-07 | — | — | US | disclosed |
| EP-1032377-A1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999026614-A1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | SLC1A2, GAP43, SCN2A | NPC1 3146/4885RAB9A 2643/4885CYP3A4 772/4885 |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | CACNA1B, CACNB2, CACNA1C | NPC1 978/4885RAB9A 2550/4885CYP3A4 1339/4885 |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, SLC1A1, SCN2A | NPC1 3014/4885RAB9A 2765/4885CYP3A4 2066/4885 |
| US-20030130295-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, GAP43, SCN2A | NPC1 3232/4885RAB9A 3400/4885CYP3A4 710/4885 |
| US-20110269785-A1 | Substituted 2-Aminoacetamides and the Use Thereof | SLC1A2, GAP43, SCN2A | NPC1 3146/4885RAB9A 2643/4885CYP3A4 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.